Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Artelo Biosciences Inc (ARTL)

Artelo Biosciences Inc (ARTL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,889
  • Shares Outstanding, K 24,494
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,650 K
  • 60-Month Beta 2.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.78
Trade ARTL with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.35
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 07/12/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 08/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +499,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7800 +4.10%
on 09/16/21
0.9940 -18.31%
on 08/27/21
-0.1015 (-11.11%)
since 08/24/21
3-Month
0.7800 +4.10%
on 09/16/21
1.2882 -36.97%
on 06/28/21
-0.4380 (-35.04%)
since 06/24/21
52-Week
0.4510 +80.04%
on 11/02/20
3.6700 -77.87%
on 02/12/21
+0.0997 (+14.00%)
since 09/24/20

Most Recent Stories

More News
Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced...

ARTL : 0.8120 (-3.33%)
KemPharm Appoints Tamara A. Seymour to Board of Directors

KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the appointment of Tamara A. Seymour to serve on its...

ARTL : 0.8120 (-3.33%)
KMPH : 9.10 (-2.15%)
Artelo Biosciences to Present at the Q3 Virtual Investor Summit on August 18th

Solana Beach, California--(Newsfile Corp. - August 11, 2021) - Artelo Biosciences, Inc., a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling...

ARTL : 0.8120 (-3.33%)
Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines

Study finds no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD

ARTL : 0.8120 (-3.33%)
Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences' CAReS Study on July 28, 2021

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system,...

ARTL : 0.8120 (-3.33%)
Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update

Enrollment in CAReS Study in patients with cancer anorexia on track to deliver first data readout by calendar year-end

ARTL : 0.8120 (-3.33%)
Artelo Biosciences to Present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14th

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system,...

ARTL : 0.8120 (-3.33%)
Artelo Biosciences Announces Two Poster Presentations Featured at the 31st Annual ICRS Symposium

Dr. Andrew Yates to Present Poster on the Company's ART27.13 Cancer Appetite Recovery Study

ARTL : 0.8120 (-3.33%)
TMP : 78.44 (+0.67%)
Artelo Biosciences to Present at the LD Micro Virtual Invitational XI on June 9th

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid...

ARTL : 0.8120 (-3.33%)
Artelo Biosciences to Participate at the Benzinga Global Small Cap Conference on May 13, 2021

La Jolla, California--(Newsfile Corp. - May 6, 2021) - , a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid...

ARTL : 0.8120 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Artelo Biosciences Inc. is a biopharmaceutical company. It is engaged in development and commercialization of proprietary therapeutics targeting the endocannabinoid system. The company's product pipeline consists of ART27.13, ART12.11 and ART26.12 which are in clinical stage. Artelo Biosciences Inc....

See More

Key Turning Points

3rd Resistance Point 0.8840
2nd Resistance Point 0.8620
1st Resistance Point 0.8370
Last Price 0.8120
1st Support Level 0.7900
2nd Support Level 0.7680
3rd Support Level 0.7430

See More

52-Week High 3.6700
Fibonacci 61.8% 2.4403
Fibonacci 50% 2.0605
Fibonacci 38.2% 1.6807
Last Price 0.8120
52-Week Low 0.4510

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar